论文部分内容阅读
目前,国内已有应用免疫疗法治疗恶性滋养细胞肿瘤的报道。我院从1978年1月至1979年12月,并用化疗及胸腺穴位埋藏免疫疗法治疗恶性滋养细胞肿瘤18例,取得了较为满意的效果。现报道如下。材料与方法一、胸腺组 18例诊断为恶性滋养细胞肿瘤的病人,平均年龄31.4岁,入院前均没有应用过化学药物治疗及免疫治疗.入院后行化疗、手术治疗及胸腺穴位埋藏免疫治疗,称为胸腺组。二、对照组同期住院的18例患恶性滋养细胞肿瘤的病人,平均年龄31.7岁,其诊断和临床分期均与所配对的胸腺组病人相同(见表),住院期间的化疗及手术治疗与所配对的病人基本一致。
At present, there are reports of using immunotherapy to treat malignant trophoblastic tumor in China. In our hospital from January 1978 to December 1979, 18 cases of malignant trophoblastic tumor were treated with chemotherapy and thymus burial immunotherapy, and satisfactory results were obtained. Report as follows now. Materials and Methods First, in the thymus group of 18 patients diagnosed with malignant trophoblastic tumor, the average age was 31.4 years old, before the hospital did not use chemical therapy and immunotherapy.After admission, chemotherapy, surgery and thymus acupoint burial immunotherapy, Known as the thymus group. Second, the control group of 18 hospitalized patients with malignant trophoblastic tumors over the same period, the average age of 31.7 years old, the diagnosis and clinical stage were the same as the matched thymus patients (see table), chemotherapy and surgical treatment during hospitalization Paired patients are basically the same.